Predictors of sacubitril/valsartan high dose tolerability in a real world population with HFrEF-Reference-Cited by-同舟云学术

Predictors of sacubitril/valsartan high dose tolerability in a real world population with HFrEF

Published:2022-06-15 Issue:5 Volume:9 Page:2909-2917
ISSN:2055-5822
Container-title:ESC Heart Failure
language:en
Short-container-title:ESC Heart Failure

Author:

Visco Valeria¹,Radano Ilaria¹,Campanile Alfonso²,Ravera Amelia²,Silverio Angelo¹,Masarone Daniele³,Pacileo Giuseppe³,Correale Michele⁴,Mazzeo Pietro⁴,Dattilo Giuseppe⁵,Giallauria Francesco⁶,Cuomo Alessandra⁶,Mercurio Valentina⁶,Tocchetti Carlo Gabriele⁶⁷⁸⁹,Di Pietro Paola¹,Carrizzo Albino¹¹⁰,Citro Rodolfo²,Galasso Gennaro¹,Vecchione Carmine¹¹⁰,Ciccarelli Michele¹

Affiliation:

1. Chair of Cardiology, Department of Medicine, Surgery and Dentistry, Schola Medica Salernitana University of Salerno Salerno Italy

2. Department of Cardiology “San Giovanni di Dio e Ruggi D'Aragona” Hopital‐University Salerno Italy

3. Heart Failure Unit AORN Colli Naples Italy

4. Cardiology Department Ospedali Riuniti University Hospital Foggia Italy

5. Department of Clinical and Experimental Medicine, Operative Unit of Cardiology University of Messina Messina Italy

6. Department of Translational Medical Sciences Federico II University Naples Italy

7. Center for Basic and Clinical Immunology Research (CISI) Federico II University Naples Italy

8. Interdepartmental Center for Clinical and Translational Research (CIRCET) Federico II University Naples Italy

9. Interdepartmental Hypertension Research Center (CIRIAPA) Federico II University Naples Italy

10. Vascular Pathophysiology Unit IRCCS Neuromed Pozzilli Italy

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ehf2.13982

Reference37 articles.

1. Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure

2. Evaluating Sacubitril/Valsartan Dose Dependence on Clinical Outcomes in Patients With Heart Failure With Reduced Ejection Fraction

3. Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM‐HF trial

4. Real‐world treatment patterns of sacubitril/valsartan: a longitudinal cohort study in Germany

5. An Early View of Real-World Patient Response to Sacubitril/Valsartan: A Retrospective Study of Patients with Heart Failure with Reduced Ejection Fraction

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of angiotensin receptor neprilysin inhibitor on physical activity in patients with heart failure with reduced ejection fraction, monitored by implantable electronic device home monitoring;Journal of Cardiovascular Medicine;2024-01-23

2. Use of sacubitril/valsartan in patients with heart failure: evidence from the real world;Expert Opinion on Pharmacotherapy;2023-12-05

3. The Long-Term Benefit of Sacubitril/Valsartan in Patients with HFrEF: A 5-Year Follow-Up Study in a Real World Population;Journal of Clinical Medicine;2023-09-28

4. Artificial intelligence in cardiovascular prevention: new ways will open new doors;Journal of Cardiovascular Medicine;2023-05

5. Effectiveness and Safety of Sacubitril/Valsartan in Patients with Chronic Kidney Disease—A Real-World Experience;Journal of Clinical Medicine;2023-02-07